Direct medical cost of lung cancer in China: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

SONG Jiafang ¹ , GUAN Haijing ^1,2 ,  LIU Gordon ^2,3

1. School of Pharmaceutical Sciences, Peking University, Beijing 100191, P.R.China;
2. Peking University China Center for Health Economic Research, Beijing 100080, P.R.China;
3. Peking University National School of Development, PKU China Center for Health Economic Research, Beijing 100871, P.R.China;

Corresponding?author：

LIU Gordon, Email: gordonliu@nsd.pku.edu.cn

Keywords：

Lung cancer; Direct medical cost; China; Systematic review

DOI：

10.7507/1672-2531.201808083

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To systematically review the direct medical cost and burden of lung cancer in Chinese population.Methods Databases such as PubMed, Scopus, CNKI, VIP and WanFang Data were searched for studies investigating cost or burden of lung cancer in Chinese population from inception to September, 2017. Based on inclusion and exclusion criteria, two researchers screened literature, extracted data, and assessed methodological quality of included studies according to methods from Molinier, LA. Descriptive analysis was used to analyze the direct medical cost in conjunction with its composition and other aspects including various costs of different therapeutic regimens and temporal trends.Results A total of 42 studies were included. The direct medical cost per person per year varied from 55 295 yuan to 77 431 yuan. In addition, the direct medical cost for hospitalization ranged from 8 582 yuan to 65 562 yuan. The cost of drug accounted for the largest part. Costs showed differences in diverse treatment regimens and time periods.Conclusions High quality studies on direct medical cost of lung cancer in China are rare. The direct medical burden of lung cancer in China is seriously high. As a consequence, control work is urgently required. Numerous factors including sample size, region, methods for dealing with data and value sets could influence the measurement results of cost. Future research could set focus on analysis based on time dimension, cost of target drug as well as the adverse effects caused by medication.

Citation： SONG Jiafang, GUAN Haijing, LIU Gordon. Direct medical cost of lung cancer in China: a systematic review. Chinese Journal of Evidence-Based Medicine, 2019, 19(1): 44-53. doi: 10.7507/1672-2531.201808083 Copy

1.	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	Karve SJ, Price GL, Davis KL, et al. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. BMC Health Services Research, 2014, 14(1): 555.
4.	Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer, 2012, 77(2): 371-375.
5.	吳一龍, 程穎, 周清, 等. 中國臨床腫瘤學會 (CSCO) 原發性肺癌診療指南 (2017.V1). 北京: 人民衛生出版社, 2017: 26-81.
6.	Thongprasert S, Permsuwan U. Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand. Curr Med Res Opin, 2017, 33(5): 955-961.
7.	Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst, 2008, 100(12): 888-897.
8.	Molinier L, Combescure C, Choua?d C, et al. Cost of lung cancer: a methodological review. Pharmacoeconomics, 2006, 24(7): 651-659.
9.	劉寶. 4 種非小細胞肺癌二線藥物治療方案費用比較研究. 中國藥房, 2010, 21(26): 2403-2406.
10.	高月霞, 肖靜, 吳徐明, 等. 1666 例肺癌患者直接住院費用構成的因子分析. 中國衛生統計, 2011, 28(3): 278-280.
11.	鮑曉蕾, 胡良平, 陳韜, 等. 甘肅省 2778 例肺癌患者住院費用影響因素分析. 軍事醫學, 2015, 39(11): 838-841.
12.	繆艷瑤, 胡欣. 某腫瘤專科醫院 2011~2013 年肺癌患者住院費用分析. 醫學信息, 2015, 28(43): 131-132.
13.	呂紅亮, 趙少峰, 謝小萍, 等. 四川省 16866 例肺癌患者住院費用影響因素分析. 中國循證醫學雜志, 2013, 13(11): 1283-1287.
14.	王亭艷, 歐陽靜. 新疆某醫院肺癌患者醫療負擔及發展趨勢研究. 醫學與社會, 2017, 30(5): 20-22.
15.	盧永吉, 胡曉斌, 寇嘉寧, 等. 蘭州市 1996~2006 年肺癌患者住院費用趨勢分析. 現代預防醫學, 2010, 37(9): 1674-1676.
16.	張云兵, 肖夢, 李韶霞, 等. 10 年間山西某綜合醫院肺癌患者住院費用影響因素分析. 衛生軟科學, 2016, 30(10): 31-35.
17.	陳麗, 馮華, 程衛華, 等. 非小細胞肺癌晚期患者醫療費用分析. 武警醫學, 2011, 22(11): 976-978.
18.	張文, 王永林, 劉寶枚, 等. 肺癌化療患者住院費用調查分析. 中國醫藥, 2016, 11(8): 1153-1156.
19.	李亞運, 錢東福, 周守君, 等. 某地區肺癌住院患者直接經濟負擔城鄉差異比較研究. 重慶醫學, 2016, 45(5): 661-663.
20.	黃海紅, 馮運, 金永春, 等. 上海某三級專科醫院住院肺癌患者經濟負擔研究. 中國醫院管理, 2012, 32(2): 57-59.
21.	王梅, 王媛媛, 郭斌, 等. 我國肺癌疾病的直接住院費用負擔現狀及其問題. 中國衛生經濟, 2007, 26(6): 59-62.
22.	馬蔚姝. 肺癌患者醫療保險費用影響因素的分析. 中國城鄉企業衛生, 2016, (3): 6-7.
23.	趙少峰, 呂紅亮, 彭映姝, 等. 肺癌患者住院費用影響因素分析—以四川省某三甲醫院為例. 預防醫學情報雜志, 2014, 30(5): 342-345.
24.	Zhou LF, Zhang MX, Kong LQ, et al. Costs, trends, and related factors in treating lung cancer patients in 67 hospitals in Guangxi, China. Cancer Invest, 2017, 35(5): 345.
25.	孫翠勇. 肺癌患者住院費用構成的因子分析. 重慶醫學, 2015, 44(28): 4005-4007.
26.	徐張燕, 周守君, 季花, 等. 某三級腫瘤專科醫院肺癌住院醫藥費用與影響因素分析. 中國腫瘤, 2015, 24(11): 915-918.
27.	常雁軍, 陳宗敏. 醫保與自費肺癌病人化療費用比較. 中國醫院管理學術年會, 2011.
28.	周彩虹, 張力建, 熊洪超, 等. 腫瘤專科醫院肺癌住院費用及相關因素的回顧調查分析. 中國醫院管理, 2010, 30(7): 37-40.
29.	武興龍, 饒江紅, 康云霞. 南昌市肺癌患者疾病經濟負擔調查. 環境衛生學雜志, 2015, 5(6): 507-511.
30.	丁婷婷, 張曉, 高翠, 等. 非小細胞肺癌患者住院費用影響因素分析及控費研究. 中國衛生統計, 2012, 29(2): 240-242.
31.	王翠娟, 尚明, 佟峰. 山東省肺癌住院患者直接經濟負擔影響因素分析. 中國醫院統計, 2016, 23(4): 254-257.
32.	杜巍, 張曉, 高翠, 等. 600 例非小細胞肺癌患者住院費用的新灰色關聯分析. 上海交通大學學報 (醫學版), 2012, 32(10): 1356.
33.	麻新梅, 張云蓮. 1192 例肺癌患者住院情況分析. 中國醫藥指南, 2007, (6): 86-87.
34.	劉媛, 陶路寧, 金永春. 肺癌患者胸腔鏡與開放手術住院費用分析. 中國病案, 2017, 18(3): 65-68.
35.	Wang BY, Huang JY, Ko JL, et al. A population-based cost analysis of thoracoscopic versus open lobectomy in primary lung cancer. Ann Surg Oncol, 2016, 23(6): 2094-2098.
36.	路慶, 韓曉梅, 郭志金, 等. 肺癌手術患者住院費用影響因素分析. 中國醫院統計, 2012, 19(3): 203-206.
37.	劉歡, 于智新, 劉曦惟, 等. 肺癌手術患者住院費用及影響因素分析. 中國衛生經濟, 2016, 35(7): 77-79.
38.	陳宗祥. 近萬例肺癌病人住院手術費用結構及趨勢分析. 中國衛生資源, 2013, 16(3): 202-204.
39.	Shi J, Zhu J. Health resource utilization in patients with advanced non-small cell lung cancer receiving chemotherapy in China. Clin Drug Investig, 2016, 36(1): 77-86.
40.	Chen W, Lin Y, Zhang L. Access to innovation and economic burden-a case of non-small cell lung cancer in a patient access program in Qingdao, China. Value Health, 2015, 18(7): A492-A492.
41.	肖海帆, 廖先珍, 許可葵, 等. 2002~2014 年 1542 例肺癌患者住院費用分析. 中國腫瘤, 2016, 25(5): 338-344.
42.	彭紅, 黃艾彌, 陶路寧, 等. 2000~2009 年肺癌患者臨床特征變化和直接醫療費用分析. 中國腫瘤, 2013, 22(8): 666-670.
43.	彭紅, 許汝言, 葉露, 等. 上海市肺癌患者疾病經濟負擔研究. 中國衛生經濟, 2015, 34(8): 78-81.
44.	Zhang X, Liu S, Liu Y, et al. Economic burden for lung cancer survivors in urban China. Int J Environ Res Public Health, 2017, 14(3): 308.
45.	Li B, Li MY, Sun LL, et al. Impact of anticancer drugs price cut on physician’s prescription choices on first-line chemotherapy regimens and health expenditure for advanced non-small cell lung cancer in China. J Thorac Dis, 2016, 8(10): 2832-2842.
46.	Chen J, Wu S, Hu C, et al. Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study. Clinicoecon Outcomes Res, 2016, 8(1): 97-111.
47.	Chen YM, Perng RP, Shih JF, et al. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. J Thorac Oncol, 2006, 1(6): 545-550.
48.	Zeng X, Karnon J, Wang S, et al. The cost of treating advanced non-small cell lung cancer: estimates from the Chinese Experience. PLOS One, 2012, 7(10): e48323.
49.	Li X, Wang Y, Wang Y, et al. Supportive care costs associated with second-line chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. Drugs Real World Outcomes, 2015, 2(1): 87-97.
50.	董佩, 毛阿燕, 邱五七, 等. 北京市本地與外地肺癌患者就診及醫療費用分析. 中國病案, 2017, 18(1): 47-50.
51.	Demeter, S J, Jacobs P, Chmielowiec C, et al. The cost of lung cancer in Alberta. Can Respir J, 2007, 14(2): 81-86.
52.	Schwarzkopf L, Wacker M, Holle R, et al. Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. Lung Cancer, 2015, 90(2): 274-280.
53.	Mahar AL, Fong R, Johnson A. PCN36 the economic impact of treating early lung cancer: a systematic review. Value Health, 2011, 14(7): A440-A440.
54.	Solem CT, Penrod JR, Lees M, et al. Cost drivers of lung cancer care: results from a retrospective chart review of pretreated advanced NSCLC patients in Europe. Value Health, 2017, 20(9): A431-A432.

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. Karve SJ, Price GL, Davis KL, et al. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. BMC Health Services Research, 2014, 14(1): 555.
4. Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer, 2012, 77(2): 371-375.
5. 吳一龍, 程穎, 周清, 等. 中國臨床腫瘤學會 (CSCO) 原發性肺癌診療指南 (2017.V1). 北京: 人民衛生出版社, 2017: 26-81.
6. Thongprasert S, Permsuwan U. Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand. Curr Med Res Opin, 2017, 33(5): 955-961.
7. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst, 2008, 100(12): 888-897.
8. Molinier L, Combescure C, Choua?d C, et al. Cost of lung cancer: a methodological review. Pharmacoeconomics, 2006, 24(7): 651-659.
9. 劉寶. 4 種非小細胞肺癌二線藥物治療方案費用比較研究. 中國藥房, 2010, 21(26): 2403-2406.
10. 高月霞, 肖靜, 吳徐明, 等. 1666 例肺癌患者直接住院費用構成的因子分析. 中國衛生統計, 2011, 28(3): 278-280.
11. 鮑曉蕾, 胡良平, 陳韜, 等. 甘肅省 2778 例肺癌患者住院費用影響因素分析. 軍事醫學, 2015, 39(11): 838-841.
12. 繆艷瑤, 胡欣. 某腫瘤專科醫院 2011~2013 年肺癌患者住院費用分析. 醫學信息, 2015, 28(43): 131-132.
13. 呂紅亮, 趙少峰, 謝小萍, 等. 四川省 16866 例肺癌患者住院費用影響因素分析. 中國循證醫學雜志, 2013, 13(11): 1283-1287.
14. 王亭艷, 歐陽靜. 新疆某醫院肺癌患者醫療負擔及發展趨勢研究. 醫學與社會, 2017, 30(5): 20-22.
15. 盧永吉, 胡曉斌, 寇嘉寧, 等. 蘭州市 1996~2006 年肺癌患者住院費用趨勢分析. 現代預防醫學, 2010, 37(9): 1674-1676.
16. 張云兵, 肖夢, 李韶霞, 等. 10 年間山西某綜合醫院肺癌患者住院費用影響因素分析. 衛生軟科學, 2016, 30(10): 31-35.
17. 陳麗, 馮華, 程衛華, 等. 非小細胞肺癌晚期患者醫療費用分析. 武警醫學, 2011, 22(11): 976-978.
18. 張文, 王永林, 劉寶枚, 等. 肺癌化療患者住院費用調查分析. 中國醫藥, 2016, 11(8): 1153-1156.
19. 李亞運, 錢東福, 周守君, 等. 某地區肺癌住院患者直接經濟負擔城鄉差異比較研究. 重慶醫學, 2016, 45(5): 661-663.
20. 黃海紅, 馮運, 金永春, 等. 上海某三級專科醫院住院肺癌患者經濟負擔研究. 中國醫院管理, 2012, 32(2): 57-59.
21. 王梅, 王媛媛, 郭斌, 等. 我國肺癌疾病的直接住院費用負擔現狀及其問題. 中國衛生經濟, 2007, 26(6): 59-62.
22. 馬蔚姝. 肺癌患者醫療保險費用影響因素的分析. 中國城鄉企業衛生, 2016, (3): 6-7.
23. 趙少峰, 呂紅亮, 彭映姝, 等. 肺癌患者住院費用影響因素分析—以四川省某三甲醫院為例. 預防醫學情報雜志, 2014, 30(5): 342-345.
24. Zhou LF, Zhang MX, Kong LQ, et al. Costs, trends, and related factors in treating lung cancer patients in 67 hospitals in Guangxi, China. Cancer Invest, 2017, 35(5): 345.
25. 孫翠勇. 肺癌患者住院費用構成的因子分析. 重慶醫學, 2015, 44(28): 4005-4007.
26. 徐張燕, 周守君, 季花, 等. 某三級腫瘤專科醫院肺癌住院醫藥費用與影響因素分析. 中國腫瘤, 2015, 24(11): 915-918.
27. 常雁軍, 陳宗敏. 醫保與自費肺癌病人化療費用比較. 中國醫院管理學術年會, 2011.
28. 周彩虹, 張力建, 熊洪超, 等. 腫瘤專科醫院肺癌住院費用及相關因素的回顧調查分析. 中國醫院管理, 2010, 30(7): 37-40.
29. 武興龍, 饒江紅, 康云霞. 南昌市肺癌患者疾病經濟負擔調查. 環境衛生學雜志, 2015, 5(6): 507-511.
30. 丁婷婷, 張曉, 高翠, 等. 非小細胞肺癌患者住院費用影響因素分析及控費研究. 中國衛生統計, 2012, 29(2): 240-242.
31. 王翠娟, 尚明, 佟峰. 山東省肺癌住院患者直接經濟負擔影響因素分析. 中國醫院統計, 2016, 23(4): 254-257.
32. 杜巍, 張曉, 高翠, 等. 600 例非小細胞肺癌患者住院費用的新灰色關聯分析. 上海交通大學學報 (醫學版), 2012, 32(10): 1356.
33. 麻新梅, 張云蓮. 1192 例肺癌患者住院情況分析. 中國醫藥指南, 2007, (6): 86-87.
34. 劉媛, 陶路寧, 金永春. 肺癌患者胸腔鏡與開放手術住院費用分析. 中國病案, 2017, 18(3): 65-68.
35. Wang BY, Huang JY, Ko JL, et al. A population-based cost analysis of thoracoscopic versus open lobectomy in primary lung cancer. Ann Surg Oncol, 2016, 23(6): 2094-2098.
36. 路慶, 韓曉梅, 郭志金, 等. 肺癌手術患者住院費用影響因素分析. 中國醫院統計, 2012, 19(3): 203-206.
37. 劉歡, 于智新, 劉曦惟, 等. 肺癌手術患者住院費用及影響因素分析. 中國衛生經濟, 2016, 35(7): 77-79.
38. 陳宗祥. 近萬例肺癌病人住院手術費用結構及趨勢分析. 中國衛生資源, 2013, 16(3): 202-204.
39. Shi J, Zhu J. Health resource utilization in patients with advanced non-small cell lung cancer receiving chemotherapy in China. Clin Drug Investig, 2016, 36(1): 77-86.
40. Chen W, Lin Y, Zhang L. Access to innovation and economic burden-a case of non-small cell lung cancer in a patient access program in Qingdao, China. Value Health, 2015, 18(7): A492-A492.
41. 肖海帆, 廖先珍, 許可葵, 等. 2002~2014 年 1542 例肺癌患者住院費用分析. 中國腫瘤, 2016, 25(5): 338-344.
42. 彭紅, 黃艾彌, 陶路寧, 等. 2000~2009 年肺癌患者臨床特征變化和直接醫療費用分析. 中國腫瘤, 2013, 22(8): 666-670.
43. 彭紅, 許汝言, 葉露, 等. 上海市肺癌患者疾病經濟負擔研究. 中國衛生經濟, 2015, 34(8): 78-81.
44. Zhang X, Liu S, Liu Y, et al. Economic burden for lung cancer survivors in urban China. Int J Environ Res Public Health, 2017, 14(3): 308.
45. Li B, Li MY, Sun LL, et al. Impact of anticancer drugs price cut on physician’s prescription choices on first-line chemotherapy regimens and health expenditure for advanced non-small cell lung cancer in China. J Thorac Dis, 2016, 8(10): 2832-2842.
46. Chen J, Wu S, Hu C, et al. Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study. Clinicoecon Outcomes Res, 2016, 8(1): 97-111.
47. Chen YM, Perng RP, Shih JF, et al. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. J Thorac Oncol, 2006, 1(6): 545-550.
48. Zeng X, Karnon J, Wang S, et al. The cost of treating advanced non-small cell lung cancer: estimates from the Chinese Experience. PLOS One, 2012, 7(10): e48323.
49. Li X, Wang Y, Wang Y, et al. Supportive care costs associated with second-line chemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. Drugs Real World Outcomes, 2015, 2(1): 87-97.
50. 董佩, 毛阿燕, 邱五七, 等. 北京市本地與外地肺癌患者就診及醫療費用分析. 中國病案, 2017, 18(1): 47-50.
51. Demeter, S J, Jacobs P, Chmielowiec C, et al. The cost of lung cancer in Alberta. Can Respir J, 2007, 14(2): 81-86.
52. Schwarzkopf L, Wacker M, Holle R, et al. Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. Lung Cancer, 2015, 90(2): 274-280.
53. Mahar AL, Fong R, Johnson A. PCN36 the economic impact of treating early lung cancer: a systematic review. Value Health, 2011, 14(7): A440-A440.
54. Solem CT, Penrod JR, Lees M, et al. Cost drivers of lung cancer care: results from a retrospective chart review of pretreated advanced NSCLC patients in Europe. Value Health, 2017, 20(9): A431-A432.

Chinese Journal of Evidence-Based Medicine

Direct medical cost of lung cancer in China: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content